Vecabrutinib

DB16657InvestigationalSmall molecule

Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₂H₂₄ClF₄N₇O₂ · 529.92 g/mol (avg)
Code names: BIIB-062 · BSK-4841 · FP-0182 · SNS-062 · WHO 10643

Resolves to

Compound

UNIIPQ7O0OB5GUCAS1510829-06-7ChEMBLCHEMBL4297640

Structure

InChIKeyQLRRJMOBVVGXEJ-XHSDSOJGSA-NSMILESNC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](NC2=CC(=CC(Cl)=C2)C(F)(F)F)C1=O)C1=NC=NC(N)=C1F

Targets

Q06187BTK

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vecabrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account